News|Articles|April 15, 2026

Refined Risk Classification Needed for Patients With CLL, Borderline IGHV Status

Fact checked by: Rose McNulty

Listen

0:00 / 0:00

Key Takeaways

Borderline IGHV cases had a higher hazard for earlier treatment initiation than mutated IGHV, with median TTFT 91.1 months versus not reached for mutated and 41.1 months for unmutated.
Reconstructed survival suggested borderline IGHV outcomes trended better than unmutated IGHV, but the difference was not statistically significant.
Notably, BCR stereotyped subset 2 was markedly overrepresented in borderline IGHV and functioned as a principal adverse prognostic driver.
Excluding subset 2 attenuated the TTFT difference between borderline and mutated IGHV, implicating biology beyond proximity to the 98% identity threshold.
Routine reporting could be strengthened by pairing the exact IGHV percent identity with BCR subset assignment, although evidence remains limited by small, retrospective cohorts and lack of novel-agent outcomes.

A new meta-analysis finds patients who have CLL with “borderline” IGHV status have intermediate outcomes, supporting the need for more precise risk classification.

Patients diagnosed with chronic lymphocytic leukemia (CLL), who have an immunoglobulin heavy chain variable region (IGHV) identity hovering close to the threshold of 98% similarity with its original germline, or template, sequence—IGHV is a segment of DNA within leukemia cells—are described as having “borderline” IGHV status (BL-IGHV).¹ This group accounts for approximately 5% of all CLL cases, according to a new meta-analysis published in Biomarker Research.

Given that CLL is the most common adult leukemia in Western countries, it represents a sizeable group of patients whose prognosis may not be accurately captured by the standard 2-group system: patients whose IGHV carries mutations (M-IGHV) and patients whose IGHV closely resembles its template (U-IGHV) in that it has at least that 98% similarity.

Why Does IGHV Status Matter?

IGHV mutational status has long been used by clinicians to predict how CLL will behave and when treatment may be needed.² Patients classified as M-IGHV are generally associated with a slower-moving disease and longer overall survival,³ whereas patients classified as U-IGHV tend to need treatment sooner and face a less favorable outlook.

For decades, the threshold of 98% similarity has separated these 2 groups. But knowing that IGHV mutation status does not change,³ what happens to patients who fall right at that boundary? Despite years of clinical observation, the biological and prognostic significance of BL-IGHV has remained controversial, with earlier studies producing conflicting results, the authors of the meta-analysis explain.

They believe their systematic review and meta-analysis to be the first to focus specifically on patients classified as BL-IGHV. Following rigorous Preferred Reporting Items for Systematic Reviews and Meta-Analyses, or PRISMA, guidelines, the researchers identified 3 studies meeting their criteria, which encompassed comparisons of time to first treatment (TTFT) and prevalence of B-cell receptor (BCR) stereotype subset 2, “which confers an adverse prognosis and has been suggested to be enriched among BL-IGHV cases,” they wrote. Overall, they pooled data from 122 patients classified as BL-IGHV, 1274 classified as M-IGHV, and 760 classified as U-IGHV.

What They Found

Patients classified as BL-IGHV needed treatment significantly sooner than patients classified as M-IGHV, with an HR of 2.28 (95% CI, 1.20-4.35), meaning their risk of needing treatment at any given point in time was more than double that of the mutated group. However, patients with BL-IGHV also fared somewhat better compared with patients with U-IGHV status, but that difference did not reach statistical significance.

When the researchers reconstructed pooled survival curves, the median TTFT was 91.1 months for the BL-IGHV group vs a median that was never reached in the M-IGHV group and 41.1 months in the U-IGHV group.

Beyond survival data, the study uncovered an important biological signal. BL-IGHV patients were far more likely to carry BCR stereotype subset 2 compared with M-IGHV and U-IGHV status. Critically, when subset 2 patients were excluded from the authors’ analysis, the survival difference between the BL-IGHV and M-IGHV groups largely disappeared. This suggests subset 2 is a key driver of the worse outcomes seen in the borderline group, not simply their position near the 98% cutoff, the authors explained.

What This Means for Patients

Their research reinforces that CLL is not a one-size-fits-all disease and that the single cutoff that long determined how patients are categorized and counseled according to their IGHV status may not fully reflect every patient’s individual biology. The authors recommend that BL-IGHV status be systematically reported alongside BCR subset information as part of routine CLL workup and that if a patient has been tested for IGHV status—typically at diagnosis or before treatment starts—that they ask their care team whether their specific percentage and BCR subset have been taken into account in their risk assessment.

The study does have limitations: all included studies were retrospective, patient numbers were relatively small, and data on overall survival and responses to newer treatments such as Bruton tyrosine kinase inhibitors or venetoclax were not available. Larger prospective studies are still needed.

References

Angotzi F, Bevilacqua A, Serafin A, et al. Outcomes of patients with CLL and borderline IGHV mutational status: a systematic review and meta analysis. Biomark Res. 2026;14(1):42. doi:10.1186/s40364-026-00913-3
Nabki J, Al Deeban B, Sium AM, et al. Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement. Leukemia. 2025;39(3):643-649. doi:10.1038/s41375-024-02499-x
Kaltwasser J. Review highlights IGHV testing complexities in CLL. AJMC. November 15, 2025. Accessed April 15, 2026. https://www.ajmc.com/view/review-highlights-ighv-testing-complexities-in-cll